ropivacaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 2403 84057-95-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ropivacaine
  • (-)-Ropivacaine
  • anapeine
  • naropeine
  • naropine
  • S-Ropivacaine
  • ropivacaine hydrochloride monohydrate
  • ropivacaine hydrochloride
  • ropivacaine HCl
An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.
  • Molecular weight: 274.41
  • Formula: C17H26N2O
  • CLOGP: 3.16
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -3.04
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 53.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 15.62 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.774 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.498 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 46.238 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 92.045 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 39.230 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 55.390 % High 1
herg hERG pIC50 4.750 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 17.418 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 158.125 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 30.680 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,MAPK7,MAPKAPK2,NTRK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK 21
kinase-selectivity-class AXL,BRAF,DDR1,EPHB4,GRK2,PDK4,SIK2 7
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.690 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.385 High 1
mh-clint Mouse hepatocyte intrinsic clearance 209.411 High 1
mppb Mouse plasma protein binding (% unbound) 45.980 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.422 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 57.710 % High 1
rat-kpuu-brain Rat brain Kpuu 1.172 % High 1
rh-clint Rat hepatocyte intrinsic clearance 270.396 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.190 % High 1
rppb Rat plasma protein binding (% unbound) 40.610 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 776.247 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 24, 1996 FDA FRESENIUS KABI USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oedema 901.18 49.37 426 8735 199869 90419417
Asthma 763.99 49.37 405 8756 241755 90377531
Wheezing 739.11 49.37 394 8767 237686 90381600
Drug hypersensitivity 575.89 49.37 429 8732 463180 90156106
Pneumonia 455.79 49.37 429 8732 637630 89981656
Vomiting 454.11 49.37 471 8690 787822 89831464
Maternal exposure during delivery 444.83 49.37 98 9063 3748 90615538
Nasal oedema 407.47 49.37 101 9060 6483 90612803
Respiratory tract infection 393.32 49.37 166 8995 58912 90560374
Dyspnoea 360.50 49.37 441 8720 880514 89738772
Local anaesthetic systemic toxicity 322.04 49.37 74 9087 3426 90615860
Generalised tonic-clonic seizure 179.83 49.37 82 9079 34821 90584465
Anaesthetic complication 173.69 49.37 42 9119 2423 90616863
Anaphylactic shock 171.50 49.37 77 9084 31540 90587746
Phrenic nerve paralysis 132.54 49.37 24 9137 326 90618960
Peripheral nerve injury 126.27 49.37 26 9135 713 90618573
Hypotension 118.99 49.37 155 9006 325242 90294044
Tracheal deviation 118.15 49.37 21 9140 255 90619031
Cardiac arrest 113.40 49.37 90 9071 104845 90514441
Cauda equina syndrome 89.71 49.37 22 9139 1345 90617941
Chest pain 85.22 49.37 131 9030 319514 90299772
Neurotoxicity 84.70 49.37 42 9119 21425 90597861
Respiratory depression 84.63 49.37 38 9123 15537 90603749
Exposure during pregnancy 84.59 49.37 112 9049 238298 90380988
Malaise 81.23 49.37 181 8980 585805 90033481
Myoclonus 80.10 49.37 39 9122 19129 90600157
Fatigue 77.96 49.37 12 9149 1154011 89465275
Diarrhoea 75.66 49.37 5 9156 939185 89680101
Paraplegia 73.97 49.37 23 9138 3389 90615897
Spinal epidural haemorrhage 71.88 49.37 14 9147 287 90618999
Cough 71.36 49.37 131 9030 368831 90250455
Motor dysfunction 71.09 49.37 36 9125 19194 90600092
Arthralgia 66.21 49.37 3 9158 778519 89840767
Epidural haemorrhage 65.24 49.37 13 9148 301 90618985
Monoplegia 64.13 49.37 21 9140 3653 90615633
Foetal heart rate abnormal 60.69 49.37 15 9146 947 90618339
Anaphylactic reaction 60.04 49.37 58 9103 87466 90531820
Vocal cord dysfunction 56.39 49.37 14 9147 900 90618386
Maternal exposure during pregnancy 56.38 49.37 117 9044 359946 90259340
Brain stem syndrome 54.42 49.37 13 9148 711 90618575
Nerve block 52.12 49.37 13 9148 852 90618434
Seizure 51.45 49.37 70 9091 152559 90466727
Labelled drug-drug interaction medication error 50.13 49.37 26 9135 14556 90604730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 184.21 32.39 68 3062 23449 42594756
Local anaesthetic systemic toxicity 173.65 32.39 39 3091 2261 42615944
Negative pressure pulmonary oedema 138.98 32.39 26 3104 599 42617606
Delayed recovery from anaesthesia 105.76 32.39 23 3107 1146 42617059
Anaesthetic complication 100.71 32.39 23 3107 1434 42616771
Cardiac arrest 96.86 32.39 73 3057 109247 42508958
Anaphylactic reaction 65.16 32.39 40 3090 42703 42575502
Hypotension 59.31 32.39 83 3047 257548 42360657
Urethral valves 58.92 32.39 11 3119 250 42617955
Bradycardia 56.20 32.39 48 3082 85436 42532769
Phrenic nerve paralysis 55.57 32.39 10 3120 184 42618021
Respiratory depression 48.79 32.39 25 3105 18843 42599362
Locked-in syndrome 48.17 32.39 10 3120 397 42617808
Incorrect route of product administration 42.86 32.39 25 3105 24280 42593925
Hyperthermia malignant 41.80 32.39 13 3117 2645 42615560
Stress cardiomyopathy 41.21 32.39 13 3117 2772 42615433
Paraplegia 39.05 32.39 13 3117 3284 42614921
Neuromuscular block prolonged 38.65 32.39 9 3121 610 42617595
Spinal cord infarction 38.00 32.39 9 3121 657 42617548
Mean arterial pressure increased 36.92 32.39 6 3124 58 42618147
Type IV hypersensitivity reaction 34.50 32.39 11 3119 2426 42615779
Recurrence of neuromuscular blockade 33.89 32.39 7 3123 271 42617934
Paralysis 32.77 32.39 14 3116 7006 42611199
Laryngospasm 32.43 32.39 10 3120 1978 42616227

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oedema 858.91 34.58 430 11689 209546 110367634
Asthma 724.23 34.58 407 11712 249884 110327296
Wheezing 692.51 34.58 398 11721 254832 110322348
Drug hypersensitivity 572.92 34.58 439 11680 453651 110123529
Local anaesthetic systemic toxicity 468.32 34.58 111 12008 5426 110571754
Maternal exposure during delivery 405.75 34.58 91 12028 3474 110573706
Nasal oedema 405.27 34.58 103 12016 6736 110570444
Vomiting 378.19 34.58 479 11640 910196 109666984
Respiratory tract infection 355.61 34.58 168 11951 71449 110505731
Pneumonia 332.12 34.58 441 11678 876273 109700907
Anaphylactic shock 322.28 34.58 142 11977 51404 110525776
Dyspnoea 283.39 34.58 463 11656 1106409 109470771
Anaesthetic complication 231.89 34.58 58 12061 3548 110573632
Cardiac arrest 183.04 34.58 160 11959 196593 110380587
Generalised tonic-clonic seizure 182.21 34.58 98 12021 54582 110522598
Phrenic nerve paralysis 179.30 34.58 34 12085 553 110576627
Hypotension 132.72 34.58 219 11900 523630 110053550
Negative pressure pulmonary oedema 125.61 34.58 26 12093 673 110576507
Tracheal deviation 114.84 34.58 21 12098 277 110576903
Respiratory depression 108.36 34.58 58 12061 31943 110545237
Anaphylactic reaction 108.26 34.58 94 12025 114206 110462974
Cauda equina syndrome 106.41 34.58 28 12091 2094 110575086
Delayed recovery from anaesthesia 105.22 34.58 28 12091 2187 110574993
Paraplegia 99.76 34.58 34 12085 6166 110571014
Diarrhoea 95.46 34.58 8 12111 1139497 109437683
Monoplegia 91.21 34.58 30 12089 4879 110572301
Peripheral nerve injury 86.61 34.58 21 12098 1127 110576053
Fatigue 86.07 34.58 15 12104 1215943 109361237
Chest pain 84.10 34.58 149 11970 376226 110200954
Neurotoxicity 80.98 34.58 53 12066 42154 110535026
Motor dysfunction 79.17 34.58 43 12076 24363 110552817
Exposure during pregnancy 78.16 34.58 94 12025 167330 110409850
Myoclonus 72.14 34.58 45 12074 32953 110544227
Malaise 69.18 34.58 195 11924 671624 109905556
Maternal exposure during pregnancy 68.99 34.58 110 12009 254773 110322407
Arthralgia 66.51 34.58 5 12114 779627 109797553
Epidural haemorrhage 66.34 34.58 14 12105 399 110576781
Seizure 66.20 34.58 100 12019 221085 110356095
Foetal heart rate abnormal 64.77 34.58 15 12104 660 110576520
Bradycardia 64.04 34.58 82 12037 155435 110421745
Incorrect route of product administration 63.28 34.58 54 12065 64007 110513173
Spinal epidural haemorrhage 63.23 34.58 13 12106 325 110576855
Rapidly progressive osteoarthritis 59.65 34.58 9 12110 31 110577149
Nerve block 57.31 34.58 14 12105 775 110576405
Wrong product administered 55.17 34.58 26 12093 10934 110566246
Vocal cord dysfunction 54.73 34.58 14 12105 936 110576244
Circulatory collapse 54.65 34.58 42 12077 42951 110534229
Spinal cord paralysis 51.16 34.58 10 12109 192 110576988
Neuromuscular block prolonged 50.96 34.58 14 12105 1233 110575947
Diplegia 50.81 34.58 16 12103 2265 110574915
Apnoea 49.78 34.58 26 12093 13613 110563567
Tachycardia 49.60 34.58 89 12030 226556 110350624
Paralysis 49.25 34.58 27 12092 15573 110561607
Stress cardiomyopathy 48.91 34.58 27 12092 15779 110561401
Cough 48.39 34.58 135 11984 461506 110115674
Pain 47.92 34.58 219 11900 954736 109622444
Tonic clonic movements 46.75 34.58 16 12103 2936 110574244
Brain stem syndrome 45.45 34.58 13 12106 1326 110575854
Ventricular fibrillation 45.30 34.58 37 12082 41276 110535904
Anaesthetic complication neurological 44.08 34.58 12 12107 1021 110576159
Arachnoiditis 43.96 34.58 12 12107 1032 110576148
Caesarean section 41.11 34.58 23 12096 13794 110563386
Acute generalised exanthematous pustulosis 41.04 34.58 27 12092 21637 110555543
Paraparesis 39.95 34.58 16 12103 4550 110572630
Product packaging confusion 39.22 34.58 9 12110 380 110576800
Nervous system disorder 38.16 34.58 30 12089 31691 110545489
Respiratory arrest 37.99 34.58 39 12080 58260 110518920
Hyperaesthesia 37.10 34.58 22 12097 14705 110562475
Diaphragmatic paralysis 37.01 34.58 11 12108 1283 110575897
Premature delivery 36.92 34.58 29 12090 30603 110546577
Spinal anaesthesia 36.67 34.58 7 12112 118 110577062
Loss of consciousness 36.60 34.58 72 12047 196234 110380946
Vitamin K deficiency 36.06 34.58 10 12109 911 110576269
Toxicity to various agents 35.93 34.58 125 11994 480430 110096750
Brachial plexopathy 35.83 34.58 8 12111 298 110576882
Locked-in syndrome 35.74 34.58 10 12109 942 110576238

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01BB09 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175682 Amide Local Anesthetic
FDA PE N0000175976 Local Anesthesia
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

N01BB Amides 10 drugs
articainebupivacainebutanilicainecinchocaineetidocainelevobupivacainelidocainemeloxicammepivacaineprilocaine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anesthesia for cesarean section indication 4847005
Local anesthesia indication 386761002
Regional Anesthesia for Labor Pain indication
Major Nerve Block for Surgery indication
Regional Anesthesia for Postoperative Pain indication
Regional Anesthesia for Surgery indication
Alcoholism contraindication 7200002
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Chronic disease of respiratory system contraindication 17097001
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Decreased cardiac function contraindication 43650005
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Paralytic ileus contraindication 55525008 DOID:8442
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Cor pulmonale contraindication 83291003 DOID:8515
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of biliary tract contraindication 105997008 DOID:9741
Procedure on urinary system contraindication 118677009
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Lesion of brain contraindication 301766008
Deficiency of cholinesterase contraindication 360607009
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic
pKa2 7.84 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel protein type 5 subunit alpha Ion channel BLOCKER IC50 4.56 IUPHAR CHEMBL
Sodium channel protein type 1 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 2 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 3 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 4 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 8 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 9 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Sodium channel protein type 10 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Potassium channel subfamily K member 3 Ion channel IC50 4.28 CHEMBL

External reference:

IDSource
4024055 VUID
N0000022060 NUI
D08490 KEGG_DRUG
132112-35-7 SECONDARY_CAS_RN
4021017 VANDF
4024055 VANDF
C0073571 UMLSCUI
CHEBI:8890 CHEBI
CHEMBL1077896 ChEMBL_ID
DB00296 DRUGBANK_ID
CHEMBL1889140 ChEMBL_ID
D000077212 MESH_DESCRIPTOR_UI
175805 PUBCHEM_CID
7602 IUPHAR_LIGAND_ID
5376 INN_ID
7IO5LYA57N UNII
1298851 RXNORM
19197 MMSL
43154 MMSL
5435 MMSL
d04051 MMSL
006248 NDDF
006249 NDDF
109094008 SNOMEDCT_US
334196006 SNOMEDCT_US
386969005 SNOMEDCT_US
725651008 SNOMEDCT_US
7IO5LYA57N INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9195 INJECTION, SOLUTION 2 mg EPIDURAL ANDA 29 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9196 INJECTION, SOLUTION 2 mg EPIDURAL ANDA 29 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9197 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 29 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9263 INJECTION 2 mg EPIDURAL ANDA 23 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9264 INJECTION 5 mg EPIDURAL ANDA 23 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9265 INJECTION 7.50 mg EPIDURAL ANDA 23 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9266 INJECTION 10 mg EPIDURAL ANDA 23 sections
NAROPIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9924 INJECTION, SOLUTION 5 mg INFILTRATION NDA 19 sections
NAROPIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9924 INJECTION, SOLUTION 5 mg INFILTRATION NDA 19 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17478-081 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 25 sections
Ropivacaine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17478-082 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 24 sections
ropivacaine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-652 INJECTION, SOLUTION 5 mg EPIDURAL ANDA 30 sections
ropivacaine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-671 INJECTION, SOLUTION 2 mg EPIDURAL ANDA 29 sections
ropivacaine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-671 INJECTION, SOLUTION 2 mg EPIDURAL ANDA 29 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-015 INJECTION 2 mg EPIDURAL ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-019 INJECTION 5 mg EPIDURAL ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-023 INJECTION 5 mg EPIDURAL ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-027 INJECTION 10 mg EPIDURAL ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-152 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-152 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-154 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
ROPIVACAINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-154 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-195 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-196 INJECTION, SOLUTION 2 mg INFILTRATION ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-197 INJECTION, SOLUTION 5 mg INFILTRATION ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-198 INJECTION, SOLUTION 5 mg INFILTRATION ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-199 INJECTION, SOLUTION 7.50 mg PERINEURAL ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-200 INJECTION, SOLUTION 10 mg EPIDURAL ANDA 26 sections
Ropivacaine Hydrochloride Human Prescription Drug Label 1 55150-201 INJECTION, SOLUTION 10 mg EPIDURAL ANDA 26 sections
Naropin HUMAN PRESCRIPTION DRUG LABEL 1 63323-285 INJECTION, SOLUTION 2 mg INFILTRATION NDA 30 sections